Shares of Corvus Pharmaceuticals Inc. (CRVS), a clinical-stage biopharmaceutical company, touched a new 52-week high of $4.35 yesterday, as the company gears up for data announcement regarding its lead drug candidate, Soquelitinib, in the coming months.
Soquelitinib (formerly known as CPI-818) is an investigational small molecule drug given orally designed to selectively inhibit ITK (interleukin-2-inducible T cell kinase), an enzyme that is expressed predominantly in T cells, and plays a role in T cell and natural killer (NK) cell immune function.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.